Proteomics

Dataset Information

0

Escherichia coli LC-MS/MS treated by tavaborole


ABSTRACT: E.coli ATCC 25922 was overnight grown in 10 ml LB and passaged for 3 h with 1:50 dilution in fresh LB. Treated with tavaborole alone (80 μg/ml, labeled ‘A’) or tavaborole plus amikacin (80 μg/ml +40 μg/ml, labeled ‘AK’) for 6 h, cells were washed in PBS and harvested by centrifugation at 4,000 g, 8 min. After liquid nitrogen flash freezing, cells were stored at -80 °C and transported to company for following experiments

INSTRUMENT(S): Q Exactive HF, Q Exactive

ORGANISM(S): Escherichia Coli

TISSUE(S): Cell Suspension Culture

SUBMITTER: Shasha Liu  

LAB HEAD: Wu Yong

PROVIDER: PXD033907 | Pride | 2023-03-10

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
P20220100109_AK1.raw Raw
P20220100109_AK2.raw Raw
P20220100109_AK3.raw Raw
P20220100109_K1.raw Raw
P20220100109_K2.raw Raw
Items per page:
1 - 5 of 7
altmetric image

Publications

Drug synergy discovery of tavaborole and aminoglycosides against Escherichia coli using high throughput screening.

Liu Shasha S   She Pengfei P   Li Zehao Z   Li Yimin Y   Li Linhui L   Yang Yifan Y   Zhou Linying L   Wu Yong Y  

AMB Express 20221201 1


High incidences of urinary tract infection (UTI) of aminoglycosides-resistant E.coli causes a severe burden for public health. A new therapeutic strategy to ease this crisis is to repurpose non-antibacterial compounds to increase aminoglycosides sensibility against multidrug resistant E.coli pathogens. Based on high throughput screening technology, we profile the antimicrobial activity of tavaborole, a first antifungal benzoxaborole drug for onychomycosis treatment, and investigate the synergist  ...[more]

Similar Datasets

2020-12-14 | GSE163091 | GEO
2020-08-27 | PXD013825 | Pride
2013-03-16 | GSE45231 | GEO
2018-11-23 | PXD009622 | Pride
2005-12-15 | GSE3577 | GEO
| PRJNA254487 | ENA
2005-05-20 | GSE2676 | GEO
2020-01-11 | GSE143418 | GEO
2020-01-28 | GSE144272 | GEO
2019-06-25 | GSE116351 | GEO